Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) Director David P. Southwell sold 10,000 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $24.05, for a total transaction of $240,500.00. Following the transaction, the director now directly owns 114,784 shares in the company, valued at $2,760,555.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Rocket Pharmaceuticals Trading Down 2.3 %
Rocket Pharmaceuticals stock traded down $0.56 during trading on Wednesday, reaching $23.69. The company had a trading volume of 297,416 shares, compared to its average volume of 712,369. Rocket Pharmaceuticals, Inc. has a 12-month low of $14.89 and a 12-month high of $32.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.80 and a current ratio of 7.80. The stock’s 50 day moving average price is $27.55 and its two-hundred day moving average price is $25.28. The firm has a market capitalization of $2.14 billion, a price-to-earnings ratio of -8.06 and a beta of 1.07.
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last announced its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.14. During the same quarter in the previous year, the firm earned ($0.92) EPS. As a group, equities analysts expect that Rocket Pharmaceuticals, Inc. will post -2.94 earnings per share for the current fiscal year.
Analysts Set New Price Targets
View Our Latest Stock Report on Rocket Pharmaceuticals
Hedge Funds Weigh In On Rocket Pharmaceuticals
Several hedge funds and other institutional investors have recently modified their holdings of RCKT. Amalgamated Bank increased its position in Rocket Pharmaceuticals by 5.4% during the 4th quarter. Amalgamated Bank now owns 8,653 shares of the biotechnology company’s stock worth $259,000 after purchasing an additional 440 shares in the last quarter. Gilder Gagnon Howe & Co. LLC boosted its holdings in Rocket Pharmaceuticals by 2.5% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 19,379 shares of the biotechnology company’s stock worth $581,000 after purchasing an additional 475 shares during the period. Metropolitan Life Insurance Co NY boosted its holdings in Rocket Pharmaceuticals by 24.0% in the fourth quarter. Metropolitan Life Insurance Co NY now owns 3,205 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 621 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Rocket Pharmaceuticals by 14.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 5,145 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 633 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in Rocket Pharmaceuticals by 3.8% in the fourth quarter. Principal Financial Group Inc. now owns 17,963 shares of the biotechnology company’s stock worth $538,000 after purchasing an additional 661 shares during the period. 98.39% of the stock is owned by institutional investors and hedge funds.
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Read More
- Five stocks we like better than Rocket Pharmaceuticals
- What Does Downgrade Mean in Investing?
- United Airlines Soars on Earnings Beat
- Consumer Staples Stocks, Explained
- J.B. Hunt Hits the Skids: Lower Prices to Come
- How to Start Investing in Real Estate
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.